Protein expression of vascular endothelial growth factor A (VEGF-A) and matrix metalloproteinase 9 (MMP-9) was studied in gastric carcinoma patients in relation to clinicopathological characteristics and prognosis. Fifty-four samples of gastric carcinoma tissue and 15 samples of adjacent normal gastric mucosal tissue were examined immunohistochemically. Expression rates of VEGF-A (66.7%) and MMP-9 (63.0%) in carcinoma tissue were significantly higher than in normal tissue (6.7% for both proteins). VEGF-A and MMP-9 expression was associated with tumour size, invasion depth, lymph node metastasis, degree of histological differentiation and pathological stage, but not age or sex. VEGF-A expression was positively correlated with that of MMP-9. Expression of VEGF-A and MMP-9 were each inversely correlated with 5-year survival. VEGF-A and MMP-9 were overexpressed in tumours compared with normal tissue; they may act together to increase carcinogenesis and the progression, invasion and metastasis of gastric carcinoma, and could be used as biomarkers for the prognosis of gastric carcinoma.
GroblewskaMMroczkoBSzmitkowskiM: The role of selected matrix metalloproteinases and their inhibitors in colorectal cancer development. Postepy Hig Med Dosw (Online)2010; 64: 22–30 [in Polish, English abstract].
8.
TuderRMYunJH: Vascular endothelial growth factor of the lung: friend or foe. Curr Opin Pharmacol2008; 8: 255–260.
9.
MroczkoBŁukaszewicz-ZajacMGuzińska-UstymowiczK: Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in gastric cancer. Folia Histochem Cytobiol2009; 47: 491–496.
10.
BorchardF: Classification of gastric carcinoma. Hepatogastroenterology1990; 37: 223–232.
11.
von RahdenBHFeithMSteinHJ: Carcinoma of the cardia: classification as esophageal or gastric cancer?Int J Colorectal Dis2005; 20: 89–93.
12.
KaseSOsakiMHonjoS: Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch2003; 442: 129–135.
13.
KallakuryBVKarikehalliSHaholuA: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res2001; 7: 3113–3119.
14.
VidalOMetgesJPElizaldeI: High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg2009; 96: 1443–1451.
15.
CabukDBasaranGCelikelC: Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology2007; 72: 111–117.
16.
SierCFKubbenFJGaneshS: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer1996; 74: 413–417.
17.
KabashimaAMaeharaYKakejiY: Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res2000; 6: 3581–3584.
18.
ZhengHTakahashiHMuraiY: Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res2006; 26: 3579–3583.
19.
YangQYeZYZhangJX: Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken)2010; 293: 2012–2019.
20.
BergersGBrekkenRMcMahonG: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol2000; 2: 737–744.
21.
LubbeWJZhouZYFuW: Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin Cancer Res2006; 12: 1876–1882.
22.
ShouYHiranoTGongY: Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer2001; 85: 1706–1712.
23.
ZuckerSMirzaHConnerCE: Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer1998; 75: 780–786.
24.
RiedelFGötteKSchwalbJ: Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol2000; 17: 1099–1105.
25.
DeryuginaEISoroceanuLStronginAY: Upregulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res2002; 62: 580–588.
26.
RayABalBSRayBK: Transcriptional induction of matrix metalloproteinase-9 in the chondrocyte and synoviocyte cells is regulated via a novel mechanism: evidence for functional cooperation between serum amyloid A-activating factor-1 and AP-1. J Immunol2005; 175: 4039–4048.
27.
BüchlerPReberHABüchlerM: Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas2003; 26: 56–64.
28.
MäättäMSoiniYLiakkaA: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res2000; 6: 2726–2734.
29.
YanoTTanikawaSFujieT: Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer2000; 36: 601–609.
YangQYeZYZhangJX: Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken)2010; 293: 2012–2019.
